^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    1d
    Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy (clinicaltrials.gov)
    P2, N=170, Terminated, Sun Yat-sen University | Recruiting --> Terminated; Since the interim results of the ADRIATIC trial presented at the ASCO Annual Meeting in June 2024, the design of the control group is no longer consistent with current clinical practice.
    Trial termination
    |
    Loqtorzi (toripalimab-tpzi)
    1d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    1d
    NeoMatryx: Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab (clinicaltrials.gov)
    P2, N=135, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    New P2 trial
    |
    Libtayo (cemiplimab-rwlc)
    1d
    A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=93, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Phase classification: P1/2 --> P2
    Trial completion • Phase classification
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    tobemstomig (RG6139)
    1d
    Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (clinicaltrials.gov)
    P1/2, N=15, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    melphalan • Opdualag (nivolumab/relatlimab-rmbw) • Melblez Kit (melphalan hepatic delivery system) • relatlimab (BMS-986016)
    1d
    This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=300, Recruiting, Innovent Biologics Technology Limited (Shanghai R&D Center) | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) (clinicaltrials.gov)
    P3, N=959, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    AFP (Alpha-fetoprotein)
    |
    Keytruda (pembrolizumab)
    1d
    Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC (clinicaltrials.gov)
    P2, N=21, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Fumena (vorolanib)
    2d
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC (clinicaltrials.gov)
    P2, N=94, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    2d
    Continuous Intrathecal Infusion of Nivolumab in Advanced Melanoma With Concomitant Leptomeningeal Disease: Efficacy, Safety, and Pharmacokinetics. (PubMed, Neurosurgery)
    These findings warrant further trials on IT nivolumab.
    PK/PD data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Opdivo (nivolumab)
    2d
    Melanoma vaccines: current R&D landscape, translational hurdles, and future outlook-a perspective drawn from 442 clinical trials. (PubMed, Front Immunol)
    Most trials focused on Stage III/IV patients (91.1%): key trials showed mRNA-4157 + pembrolizumab reduced recurrence/death risk by 49% in resected melanoma, and herpes simplex virus RP1 + nivolumab achieved 58.3% objective response rate (ORR) in ICI-resistant patients. However, challenges include tumor heterogeneity, immunosuppressive tumor microenvironment (TME), inefficient delivery, geographical R&D imbalance, and low Phase III conversion. Interdisciplinary collaboration, international multicenter trials, optimized clinical design (e.g., early-stage patient enrollment), and policy support are needed to advance their clinical translation.
    Review • Journal
    |
    IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • intismeran autogene (mRNA-4157)